Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Privia Health (PRVA) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Privia Health (PRVA) over the last 6 years, with Q3 2025 value amounting to $441.4 million.

  • Privia Health's Cash & Equivalents rose 458.65% to $441.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.4 million, marking a year-over-year increase of 458.65%. This contributed to the annual value of $491.1 million for FY2024, which is 2609.37% up from last year.
  • Latest data reveals that Privia Health reported Cash & Equivalents of $441.4 million as of Q3 2025, which was up 458.65% from $390.1 million recorded in Q2 2025.
  • In the past 5 years, Privia Health's Cash & Equivalents registered a high of $491.1 million during Q4 2024, and its lowest value of $81.9 million during Q1 2021.
  • Its 5-year average for Cash & Equivalents is $349.4 million, with a median of $348.0 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Privia Health's Cash & Equivalents was 28556.96% (2022), while the steepest drop was 1248.67% (2022).
  • Quarter analysis of 5 years shows Privia Health's Cash & Equivalents stood at $320.6 million in 2021, then increased by 8.55% to $348.0 million in 2022, then grew by 11.93% to $389.5 million in 2023, then grew by 26.09% to $491.1 million in 2024, then dropped by 10.14% to $441.4 million in 2025.
  • Its Cash & Equivalents stands at $441.4 million for Q3 2025, versus $390.1 million for Q2 2025 and $469.3 million for Q1 2025.